To overcome the challenges of accessibility in lab automation, Beam Therapeutics partnered with Artificial. Learn more about Beam's automation journey and how they made automation accessible to all with Artificial.
Artificial raised a $21.5M Series A investment round led by led by M12, Microsoft’s venture fund, along with Playground Global and AME Cloud Ventures.
Nikhita Singh, Artificial’s CPO, joined Marshall Brennan, Scientific Director at SLAS, to chat about how Artificial empowers scientists to easily and quickly automate their experiments.
